SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
The number of shares and votes in Active Biotech has changed as a result of the recently completed rights issue.
Today, the last trading day of the month, there are in total 96,824,320 shares and votes in Active Biotech.
For further information, please contact:
Tomas Leanderson, CEO
Tel: +46 (0)46 19 20 95
E-mail: [email protected]
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
E-mail: [email protected]
Active Biotech AB
P.O. Box 724, SE-220 07 Lund, Sweden
Phone +46 (0)46 19 20 00
Active Biotech AB (publ) (Nasdag Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal Phase 3 development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.
Active Biotech is required to publish the information contained in this press release in accordance with the Financial Instruments Trading Act. This information was provided to the media for publication at 08.30 am CET on December 30, 2016.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/c8d7f1ff-19bb-4c24-8286-00ca44067514
